The 36-month beta value for IART is at 1.08. Analysts have varying views on the stock, with 4 analysts rating it as a “buy,” 5 rating it as “overweight,” 6 as “hold,” and 0 as “sell.”
The public float for IART is 65.08M, and currently, shorts hold a 7.86% of that float. The average trading volume for IART on November 05, 2024 was 910.07K shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
IART) stock’s latest price update
Integra Lifesciences Holdings Corp (NASDAQ: IART)’s stock price has plunge by 25.10relation to previous closing price of 19.28. Nevertheless, the company has seen a 24.84% surge in its stock price over the last five trading sessions. seekingalpha.com reported 2024-11-04 that Integra LifeSciences Holdings Corporation (NASDAQ:IART ) Q3 2024 Earnings Call Transcript November 4, 2024 8:30 AM ET Company Participants Chris Ward – IR Stuart Essig – Executive Chairman Jan De Witte – President and CEO Lea Knight – CFO Conference Call Participants Steven Lichtman – Oppenheimer Vik Chopra – Wells Fargo Ryan Zimmerman – BTIG Kristen Stewart – C.L. King Robbie Marcus – JPMorgan Matt Taylor – Jefferies Richard Newitter – Truist Securities Craig Bijou – Bank of America Securities Joanne Wuensch – Citi Chris Ward Good morning and thank you for joining the Integra LifeSciences Third Quarter 2024 Earnings Conference Call.
IART’s Market Performance
Integra Lifesciences Holdings Corp (IART) has seen a 24.84% rise in stock performance for the week, with a 41.88% gain in the past month and a 5.88% surge in the past quarter. The volatility ratio for the week is 6.35%, and the volatility levels for the past 30 days are at 4.26% for IART. The simple moving average for the past 20 days is 24.22% for IART’s stock, with a -15.57% simple moving average for the past 200 days.
Analysts’ Opinion of IART
Citigroup, on the other hand, stated in their research note that they expect to see IART reach a price target of $23, previously predicting the price at $30. The rating they have provided for IART stocks is “Sell” according to the report published on July 30th, 2024.
BTIG Research gave a rating of “Sell” to IART, setting the target price at $22 in the report published on July 30th of the current year.
IART Trading at 29.03% from the 50-Day Moving Average
After a stumble in the market that brought IART to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -46.90% of loss for the given period.
Volatility was left at 4.26%, however, over the last 30 days, the volatility rate increased by 6.35%, as shares surge +38.38% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +14.48% upper at present.
During the last 5 trading sessions, IART rose by +24.84%, which changed the moving average for the period of 200-days by -43.10% in comparison to the 20-day moving average, which settled at $19.42. In addition, Integra Lifesciences Holdings Corp saw -44.62% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at IART starting from Mosebrook Jeffrey, who sale 1,191 shares at the price of $21.58 back on Aug 19 ’24. After this action, Mosebrook Jeffrey now owns 36,088 shares of Integra Lifesciences Holdings Corp, valued at $25,701 using the latest closing price.
ESSIG STUART, the Exec. Chairman of the Board of Integra Lifesciences Holdings Corp, purchase 52,641 shares at $28.49 during a trade that took place back on May 23 ’24, which means that ESSIG STUART is holding 487,922 shares at $1,499,979 based on the most recent closing price.
Stock Fundamentals for IART
Current profitability levels for the company are sitting at:
- 0.08 for the present operating margin
- 0.57 for the gross margin
The net margin for Integra Lifesciences Holdings Corp stands at 0.02. The total capital return value is set at 0.03. Equity return is now at value -0.42, with 0.60 for asset returns.
Based on Integra Lifesciences Holdings Corp (IART), the company’s capital structure generated 0.55 points at debt to capital in total, while cash flow to debt ratio is standing at 0.08. The debt to equity ratio resting at 1.2. The interest coverage ratio of the stock is 1.9.
Currently, EBITDA for the company is 297.59 million with net debt to EBITDA at 7.72. When we switch over and look at the enterprise to sales, we see a ratio of 2.34. The receivables turnover for the company is 5.64for trailing twelve months and the total asset turnover is 0.38. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.39.
Conclusion
In conclusion, Integra Lifesciences Holdings Corp (IART) has had a mixed performance lately. Opinion on the stock among analysts is mixed, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
